Skip to main content
Clinical Trials/KCT0005161
KCT0005161
Completed
未知

The feasibility of MRI-based techniques for the evaluation of non-alcoholic fatty liver disease

Gachon University Gil Medical Center0 sites20 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Gachon University Gil Medical Center
Enrollment
20
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Observational Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Korean males aged 20 to under 40 at the time of screening
  • Those who are over 50 kg and have a body mass index (kg per meter squared) of 18\.5 or more and less than 28
  • No congenital or chronic disease requiring treatment and no medical condition or findings as a result of medical examination
  • A person who is determined to be suitable as a clinical test subject as a result of laboratory tests, such as a questionnaire and physical examination, serum test, hematology test, blood chemistry test and urine test
  • A person who, after hearing and fully understanding the details of this clinical trial, voluntarily decided to participate and agrees in writing to follow the precautions

Exclusion Criteria

  • Those whose AST and ALT exceed 2 times the upper limit of the normal range
  • A person who is unable to handle the noise or isolation environment in the test equipment at the MRI laboratory or contraindicated for MRI examination
  • Subjects diagnosed with alcoholic liver disease
  • Other identified liver diseases: hepatitis B or C, autoimmune hepatitis, drug\-induced liver damage, other liver diseases.
  • Subjects with cirrhosis or biliary tract disease
  • A history of taking medications that cause secondary fatty liver within the last year
  • (corticosteroids, tamoxifen, amiodarone, methotrexate, etc.),
  • Patients with diabetes
  • Complications of diabetes/hypertension/other metabolic diseases or related diseases (ischemic heart disease, heart failure, chronic kidney disease stage \=3\)
  • Persons deemed unsuitable due to other severe systemic diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials